Efecto de la modulación de PPARᵧ sobre la vía reversa del colesterol.
Saved in:
| Title: | Efecto de la modulación de PPARᵧ sobre la vía reversa del colesterol. |
|---|---|
| Authors: | Díaz López, Mónica María1, Serrano Triana, Daniel Mauricio1,2, Martínez Forero, Iván Efraín1, Arcila, Darío Echeverri3, Buitrago, Lorena3, Losada, Fernando Lizcano3 fernando.lizcano@unisabana.edu.co |
| Source: | MedUNAB. dic2006, Vol. 9 Issue 3, p192-197. 6p. |
| Subjects: | CELL receptors, LIVER cells, CHOLESTEROL, LIPID metabolism, PEROXISOMES |
| Geographic Terms: | NEW Zealand |
| Abstract (English): | Introduction: Nuclear receptor LXRα (liver X receptor alpha) has a beneficial effect on the reverse pathway of cholesterol and reverts some defects in the lipid metabolism that are related with cardiovascular risk. LXRα activity is modulated by agonists of the nuclear receptor PPARγִ (Peroxisome Proliferator-Activated Receptor gamma), that are used for type 2 Diabetes treatment. Objective: To observe LXRα gene expression and some genes that it regulates, after the treatment with a PPARγ agonist in the absence of estrogens. Method: 18 New Zealand female rabbits were ophorectomized. Three groups selected themselves randomly. In two groups, were treated with hypercholesterolemic diet during 3 weeks alternating with normal diet for a total of 24 weeks, to one of these groups, administered placebo (group 1, n=6) and to another one rosiglitazone 3 mg/Kg/día (group 2, n=6). The third group took like group control with normal diet. The expression of the genes of lxrα, abca1 and il-1β? was determined by means of RT-PCR. Results: An increase in LXRά mRNA expression was observed in liver, without any variation in ABCA1 in artery. A reduction on IL-1β levels in artery after rosiglitazone therapy was observed. Conclusion: PPARγ activation increases LXRα function in the absence of estrogens. However PPARγ might execute some beneficial effect on reverse cholesterol pathway in a different route from LXRα/ABCA1 pathway. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | Introducción: El receptor nuclear LXRαִ (liver receptor X alfa) tiene un efecto benéfico en la vía reversa de colesterol y revierte algunas anomalías del metabolismo lipídico relacionadas con el riesgo cardiovascular. Su actividad es en parte modulada positivamente por los agonistas del receptor nuclear PPARγִ (Peroxisome Proliferator-Activated Receptor Gamma), utilizados para la terapia de la diabetes tipo 2. Objetivo: Observar la expresión de LXRα y algunos de los genes que regula, tras la utilización de un agonista de PPARγִ eṇ condicione dẹ bajọ nivẹl de estrógenos. Método: 18 conejas New Zealand fueron sometidas a ooforectomía quirúrgica. Luego se seleccionaron aleatoriamente 3 grupos. En dos grupos, se manejó una dieta hipercolesterolémica durante 3 semanas alternando con dieta normal para un total de 24 semanas, a uno de estos grupos, se le administró placebo (grupo 1, n=6) y a otro rosiglitazona 3 mg/Kg/día (grupo 2, n=6). El tercer grupo se tomó como grupo control con dieta normal. Se determinó la expresión de los genes de lxrα, abca1 e il-1β mediante RT-PCR. Resultados: Se observó un incremento en los niveles de LXRά en hígado, pero no se observó variación de ABCA1 en arteria, con disminución de IL-1β en arteria tras la terapia con rosiglitazona. Conclusión: La activación de PPARγ aumenta la función de LXRαִ eṇ ausencia de estrógenos. Sin embargo algunos efectos benéficos de PPARγ en la vía reversa de colesterol podría tener una vía alterna a la de LXRα/ABCA1. [ABSTRACT FROM AUTHOR] |
| Copyright of MedUNAB is the property of Universidad Autonoma de Bucaramanga, UNAB and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
Be the first to leave a comment!
